Author details

Full Name

Janessa Laskin

Affiliation

ORCID

Career Start Year

1996

Papers

149

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36982943	Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study.	Int J Mol Sci	2023
37820295	Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline.		2023
37558751	Chemokine expression predicts T cell-inflammation and improved survival with checkpoint inhibition across solid cancers.	NPJ Precis Oncol	2023
37623024	Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression.	Curr Oncol	2023
37622996	Real-World Clinical Outcomes for Patients with <i>EGFR</i> and <i>HER2</i> Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer.	Curr Oncol	2023
36656302	A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.	Future Oncol	2023
36964191	Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration.	NPJ Precis Oncol	2023
35140225	A platform for oncogenomic reporting and interpretation.	Nat Commun	2022
35691590	Whole-genome and transcriptome analysis enhances precision cancer treatment options.	Ann Oncol	2022
35498385	Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report.	JTO Clin Res Rep	2022
36209277	Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma.	Nat Commun	2022
35623671	Hyper-Sensitive? Targeted Therapy With a Primed Immune System.	J Thorac Oncol	2022
35367630	The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space.	J Mol Diagn	2022
36071521	TMBur: a distributable tumor mutation burden approach for whole genome sequencing.	BMC Med Genomics	2022
35483882	Whole-genome and transcriptome analysis of advanced adrenocortical cancer highlights multiple alterations affecting epigenome and DNA repair pathways.	Cold Spring Harb Mol Case Stud	2022
35923926	The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer.	Ther Adv Med Oncol	2022
35726793	Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis.	Melanoma Res	2022
36661661	Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study.	Curr Oncol	2022
35257510	The impact of whole genome and transcriptome analysis (WGTA) on predictive biomarker discovery and diagnostic accuracy of advanced malignancies.	J Pathol Clin Res	2022
34843087	Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care.	J Community Genet	2022
34931022	Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury.	NPJ Precis Oncol	2021
34152087	Clinical and cost outcomes following genomics-informed treatment for advanced cancers.	Cancer Med	2021
33768871	NTRK2 Fusion driven pediatric glioblastoma: Identification of oncogenic Drivers via integrative Genome and transcriptome profiling.	Clin Case Rep	2021
33372414	Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma.	Cancer Med	2021
33148671	Uncovering Clinically Relevant Gene Fusions with Integrated Genomic and Transcriptomic Profiling of Metastatic Cancers.	Clin Cancer Res	2021
33237632	Matching methods in precision oncology: An introduction and illustrative example.	Mol Genet Genomic Med	2021
33020056	Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.	Clin Cancer Res	2021
32958704	Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?	Clin Cancer Res	2021
32852072	Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.	Oncologist	2021
32847480	Evaluating genomic biomarkers associated with resistance or sensitivity to chemotherapy in patients with advanced breast and colorectal cancer.	J Oncol Pharm Pract	2021
33051307	Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics.	Clin Cancer Res	2021
34788622	Rearrangement-mediated cis-regulatory alterations in advanced patient tumors reveal interactions with therapy.	Cell Rep	2021
31481506	Altered Gene Expression along the Glycolysis-Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer.	Clin Cancer Res	2020
32020438	A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies.	Invest New Drugs	2020
31907737	Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis.	Invest New Drugs	2020
31630293	Emotional distress and psychosocial needs in patients with breast cancer in British Columbia: younger versus older adults.	Breast Cancer Res Treat	2020
32169783	A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226.	Lung Cancer	2020
32051610	Author Correction: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution.	Nat Genet	2020
31769875	Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.	Cancer	2020
31932696	Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution.	Nat Genet	2020
31871216	Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic <i>DPYD</i> structural variant.	Cold Spring Harb Mol Case Stud	2020
32151517	Integration of Whole-Genome Sequencing With Circulating Tumor DNA Analysis Captures Clonal Evolution and Tumor Heterogeneity in Non-V600 BRAF Mutant Colorectal Cancer.	Clin Colorectal Cancer	2020
33134827	Establishing a Framework for the Clinical Translation of Germline Findings in Precision Oncology.	JNCI Cancer Spectr	2020
32916265	NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.	Ann Oncol	2020
32518206	Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types.	Mol Cancer Ther	2020
32624572	Improved structural variant interpretation for hereditary cancer susceptibility using long-read sequencing.	Genet Med	2020
32953487	EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes.	Transl Lung Cancer Res	2020
32846061	Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid Cancers.	N Engl J Med	2020
35050743	Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories.	JCO Precis Oncol	2020
35121966	Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes.	Nat Cancer	2020